AgomAb Therapeutics AGMB
NASDAQ AGMB
$8.73 +0.50 (+6.08%)
At close: Oct 20, 2026 · 4:00 PM EDT

AgomAb Therapeutics NV (AGMB) Total Non-Current Liabilities (2024 - 2026)

Updated

Agomab Therapeutics (AGMB) reported Total Non-Current Liabilities of $6.37 million for Q2 2026.

Analysis

AgomAb Therapeutics NV (AGMB) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends

At the end of FY2025, Agomab Therapeutics posted Total Non-Current Liabilities of $4.76 million, down 51.9% from FY2024.

  • By year, Total Non-Current Liabilities came in at $9.9 million in FY2024.
  • The Q2 2026 figure ranks as the highest quarterly Total Non-Current Liabilities since Q4 2024.
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 6.25 Mn
Dec 31, 2025 4.95 Mn
Dec 31, 2024 9.52 Mn
API Access

AgomAb Therapeutics NV Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=AGMB&period=max&api_key=YOUR_API_KEY